CASIF — CASI Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.06m
- $38.79m
- $20.71m
Brief: Casi Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339
U.S. STOCKS ON THE MOVE-Trip.com, Verizon Communications, Netflix
Brief: Casi Pharmaceuticals' Partner Juventas's New Drug Application For Cnct19 Accepted By China National Medical Products Administration
CASI Pharmaceuticals up on Chinese nod for cancer therapy application
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
Brief: Casi Pharmaceuticals Announces Third Quarter 2022 Financial Results
Casi Pharmaceuticals Inc Expected To Post A Loss Of 46 Cents A Share: Earnings Preview
Brief: Casi Pharma Exits Juventas Investment To Strengthen Balance Sheet
U.S. RESEARCH ROUNDUP- PLx pharma, Vroom, Walmart
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: CASI Pharmaceuticals reports Q2 results
Casi Pharmaceuticals Inc Expected To Post A Loss Of 64 Cents A Share: Earnings Preview
Brief: Casi Pharmaceuticals Announces Precision Autoimmune Therapeutics Has Completed First-Round Financing Of $21 Mln
Brief: Casi Pharmaceuticals Announces Reverse Stock Split
Brief: Casi Pharmaceuticals Inc - On May 23, Terminated Original License Agreement Dated Sept 17, 2014 Between Spectrum Pharmaceuticals Cayman, Lp, Co
Brief: Casi Pharmaceuticals Enters Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-Cd38 Monoclonal Antibody Cid-103 In Autoimmune Field
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Casi Pharmaceuticals Announces First Quarter 2022 Financial Results
Casi Pharmaceuticals Inc Expected To Post A Loss Of 9 Cents A Share: Earnings Preview